-

FairJourney Bio Launches Cryo-EM Services With Advanced Laboratories in San Diego, USA

Expanded offering provides high-resolution structural insights to support antibody discovery and biologic design

PORTO, Portugal and SAN DIEGO, Calif.--(BUSINESS WIRE)--FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced the expansion of its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the Company’s advanced laboratories in San Diego, CA.

This strategic addition strengthens FJBio’s position as a trusted partner for pharmaceutical and biotechnology companies worldwide by providing accessible, high-resolution structural insights that accelerate antibody discovery, selection, and design. By combining cutting-edge technology with FJBio’s team of expert scientists, the service offering ensures partners gain access to top-quality data and receive comprehensive guidance throughout the discovery and development process.

Benefitting from industry-leading, high-throughput cryo-EM capabilities, utilizing two state-of-the-art ThermoFisher Titan Krios 5 systems, the cryo-EM services enable rapid and scalable analysis, with models delivered within 2-3 weeks from sample delivery. The offering supports both intermediate- and high-resolution validation of proteins, protein-protein, and protein-ligand complexes, producing high-quality and highly interpretable protein structures to inform confident decision-making.

Tailored specifically for antibody discovery, the cryo-EM services deliver value across the R&D value chain, supporting programs from early evaluation through to advanced optimization:

  • Evaluation – Early structural insights into epitope diversity of immune libraries
  • Discovery – cryo-EM-based hit discovery supported by sequence-from-structure workflows
  • Selection – Structure-informed insights into therapeutic binding modes to guide lead selection
  • Control – Computational protein design campaigns and development of next-generation synthetic libraries

Dr. Werner Lanthaler, Chief Executive Officer of FairJourney Bio, commented:Cryo-EM enables unique and powerful insights into molecular structures and interactions at an atomic level. Adding structure-based information from real-world images is a paradigm shift that allows researchers to de-risk their R&D projects along the entire value chain. The improved resolution removes guesswork at critical junctures in the R&D process and thus serves to both accelerate discovery projects as well as improving their success rates. FJBio’s cryo-EM platform with a dedicated team of experts is unmatched in terms of speed, scale and quality.”

With the addition of cryo-EM services, supported by our high-end San Diego labs, we can provide our partners with the structural precision and expert support needed to accelerate the development of next-generation therapies,” said Dr. Christopher Arthur, CSO Structural Biology, FairJourney Bio.

For more information, visit: https://fjbio.com/fjb-cryo-em

Contacts

For high resolution images, contact Zyme Communications
Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

FairJourney Bio


Release Versions

Contacts

For high resolution images, contact Zyme Communications
Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

Social Media Profiles
More News From FairJourney Bio

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA. With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage developme...

FairJourney Biologics Appoints Dr. Werner Lanthaler as Chief Executive Officer

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A. (FJBio), a global leader in antibody discovery and development, today announced that Dr. Werner Lanthaler has been appointed Chief Executive Officer (CEO) to further strengthen its global position as an integrated powerhouse of efficient antibody discovery and development. After nearly 14 years leading FairJourney Biologics, Founder António Parada will focus on driving FJBio’s innovation strategy on the Supervisory Board. Dr. Werner L...

FairJourney Biologics Establishes Supervisory Board

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A., global leader in antibody discovery and development, today announced the formation of its Supervisory Board to support the Company’s ongoing strategy for growth and innovation. Comprising experienced biotech leaders with proven track records for success, the strategic initiative will focus on driving cutting-edge research, reinforcing the Company’s commitment to excellence in antibody research and to accelerate innovation in the fiel...
Back to Newsroom